Abstract

http://ssrn.com/abstract=397040
 


 



Law, Policy, and Market Implications of Genetic Profiling in Drug Development


Michael J. Malinowski


Louisiana State University, Baton Rouge - Paul M. Hebert Law Center


Houston Journal of Health Law & Policy, Vol. 2, pp. 31-63, 2002

Abstract:     
Completion of a map of the human genome and the explosive emergence of a multitude of complementary technologies ranging from DNA chips to sophisticated software have transformed great expectations for genetic medicine into goals potentially obtainable in the foreseeable future. Drug development now encompasses extensive genetic profiling, a field known as pharmacogenomics, which introduces tremendous potential to increase human health and capital - specially through more precise utilization of pharmaceuticals. Accordingly, the legal, medical and life science communities must rise to the challenge of working through the complexities associated with pharmacogenomics rather than continuing to assume the luxury of time.

JEL Classification: IO, I1, K2, O0

Accepted Paper Series


Not Available For Download

Date posted: May 28, 2003  

Suggested Citation

Malinowski, Michael J., Law, Policy, and Market Implications of Genetic Profiling in Drug Development. Houston Journal of Health Law & Policy, Vol. 2, pp. 31-63, 2002. Available at SSRN: http://ssrn.com/abstract=397040

Contact Information

Michael J. Malinowski (Contact Author)
Louisiana State University, Baton Rouge - Paul M. Hebert Law Center ( email )
440 Law Center Building
Baton Rouge, LA 70803
United States
225-578-8716 (Phone)
Feedback to SSRN


Paper statistics
Abstract Views: 385

© 2014 Social Science Electronic Publishing, Inc. All Rights Reserved.  FAQ   Terms of Use   Privacy Policy   Copyright   Contact Us
This page was processed by apollo7 in 0.281 seconds